- Home
- PRLD vs SACH Comparison
PRLD vs SACH Comparison
Compare PRLD & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- SACH
- Stock Information
- Founded
- PRLD 2016
- SACH 2010
- Country
- PRLD United States
- SACH United States
- Employees
- PRLD N/A
- SACH N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- SACH Real Estate Investment Trusts
- Sector
- PRLD Health Care
- SACH Real Estate
- Exchange
- PRLD Nasdaq
- SACH Nasdaq
- Market Cap
- PRLD 50.1M
- SACH 46.2M
- IPO Year
- PRLD 2020
- SACH 2017
- Fundamental
- Price
- PRLD $0.89
- SACH $0.99
- Analyst Decision
- PRLD Strong Buy
- SACH Hold
- Analyst Count
- PRLD 2
- SACH 3
- Target Price
- PRLD $4.50
- SACH $2.25
- AVG Volume (30 Days)
- PRLD 137.5K
- SACH 287.8K
- Earning Date
- PRLD 05-06-2025
- SACH 05-01-2025
- Dividend Yield
- PRLD N/A
- SACH 18.24%
- EPS Growth
- PRLD N/A
- SACH N/A
- EPS
- PRLD N/A
- SACH N/A
- Revenue
- PRLD $7,000,000.00
- SACH N/A
- Revenue This Year
- PRLD N/A
- SACH N/A
- Revenue Next Year
- PRLD N/A
- SACH $4.52
- P/E Ratio
- PRLD N/A
- SACH N/A
- Revenue Growth
- PRLD N/A
- SACH N/A
- 52 Week Low
- PRLD $0.61
- SACH $0.80
- 52 Week High
- PRLD $6.80
- SACH $3.16
- Technical
- Relative Strength Index (RSI)
- PRLD 51.42
- SACH 52.18
- Support Level
- PRLD $0.77
- SACH $0.90
- Resistance Level
- PRLD $1.00
- SACH $0.98
- Average True Range (ATR)
- PRLD 0.11
- SACH 0.05
- MACD
- PRLD -0.01
- SACH 0.01
- Stochastic Oscillator
- PRLD 37.18
- SACH 93.37
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.